Inhibikase Therapeutics (IKT) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) PT Lowered to $92 at Mizuho
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
